Building Complexity and Achieving Selectivity through Catalysis – Case Studies from the Pharmaceutical Pipeline
Matthew G. Beaver
a
Amgen Inc., Process Development, Drug Substance Technologies, 360 Binney Street, Cambridge, Massachusetts, United States
,
Seb Caille
b
Amgen Inc., Process Development, Drug Substance Technologies, One Amgen Center Drive, Thousand Oaks, California 91320, United States Email: jtedrow@amgen.com Email: othiel@amgen.com
,
Robert P. Farrell
b
Amgen Inc., Process Development, Drug Substance Technologies, One Amgen Center Drive, Thousand Oaks, California 91320, United States Email: jtedrow@amgen.com Email: othiel@amgen.com
,
Andreas R. Rötheli
a
Amgen Inc., Process Development, Drug Substance Technologies, 360 Binney Street, Cambridge, Massachusetts, United States
,
Austin G. Smith
b
Amgen Inc., Process Development, Drug Substance Technologies, One Amgen Center Drive, Thousand Oaks, California 91320, United States Email: jtedrow@amgen.com Email: othiel@amgen.com
,
Jason S. Tedrow∗
a
Amgen Inc., Process Development, Drug Substance Technologies, 360 Binney Street, Cambridge, Massachusetts, United States
,
Oliver R. Thiel∗
a
Amgen Inc., Process Development, Drug Substance Technologies, 360 Binney Street, Cambridge, Massachusetts, United States